SLCO1B3

Solute carrier organic anion transporter family member 1B3 · Q9NPD5 · SLCO1B3 on Sugi Atlas →

93,895 patent compounds predicted against SLCO1B3, 74,755 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Erythromycin Propionate (SCHEMBL3331)	1.00	3/20
Erythromycin Ethylsuccinate (SCHEMBL18259)	1.00	3/20
Dihydrokaempferol (SCHEMBL39319)	0.54	3/20
Rifamycin (SCHEMBL2320)	1.00	2/20
Vinblastine (SCHEMBL3628)	1.00	2/20
Vinblastine (SCHEMBL3629)	1.00	2/20
Vincristine (SCHEMBL3709)	1.00	2/20
Atorvastatin (SCHEMBL3832)	1.00	2/20
Vincristine (SCHEMBL3999)	1.00	2/20
Vinblastine (SCHEMBL6146)	1.00	2/20
Beta Carotene (SCHEMBL6151)	1.00	2/20
Glycyrrhizin (SCHEMBL17684)	1.00	2/20
Gilretinol Acetate (SCHEMBL21588)	1.00	2/20
Gilretinol Acetate (SCHEMBL21589)	1.00	2/20
Rifampin (SCHEMBL23490)	1.00	2/20
Rifampin (SCHEMBL23491)	1.00	2/20
Rifampin (SCHEMBL23492)	1.00	2/20
Clarithromycin (SCHEMBL38124)	1.00	2/20
Clarithromycin (SCHEMBL38125)	1.00	2/20
Atorvastatin (SCHEMBL28456)	0.98	2/20

Clinical trials — most relevant to SLCO1B3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
The Interaction of Herbs and Statins	PHASE4	COMPLETED
Drug Transporter Interaction Study PHENTRA_2015_KPUK	PHASE4	COMPLETED
Confirmatory Study of Govorestat in CMT-SORD	PHASE3	WITHDRAWN
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)	PHASE3	RECRUITING
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®	PHASE1/PHASE2	COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	PHASE1	RECRUITING
Statin Therapy to Improve Medication Adherence	PHASE1	COMPLETED
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling	PHASE1	COMPLETED
A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors	PHASE1	RECRUITING
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study	EARLY_PHASE1	NOT_YET_RECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SLCO1B3 binder may also engage these)

Protein	Name	Similarity
Q9QZX8	—	1.000	Q9QZX8 →
Q9JJL3	—	1.000	Q9JJL3 →
F5H094	—	1.000	F5H094 →
Q9NYB5	—	1.000	Q9NYB5 →
SLCO1B1	Solute carrier organic anion transporter family member 1B1	1.000	landscape →
Q99J94	—	1.000	Q99J94 →
G3V0H7	—	1.000	G3V0H7 →
Q9QYE2	—	1.000	Q9QYE2 →
P46720	—	1.000	P46720 →
Q9ERB5	—	1.000	Q9ERB5 →
P70502	—	0.999	P70502 →
Q9EP96	—	0.999	Q9EP96 →
Q9EPZ7	—	0.999	Q9EPZ7 →
Q91YY5	—	0.998	Q91YY5 →
Q9GMU6	—	0.998	Q9GMU6 →
Q9QXZ6	—	0.998	Q9QXZ6 →
SLCO1A2	Solute carrier organic anion transporter family member 1A2	0.996	landscape →
O35913	—	0.996	O35913 →
O88397	—	0.994	O88397 →
Q8C0X7	—	0.992	Q8C0X7 →
Q9UIG8	—	0.992	Q9UIG8 →
Q9VVH9	—	0.991	Q9VVH9 →
Q86UG4	—	0.991	Q86UG4 →
Q5RFF0	—	0.991	Q5RFF0 →
SLCO4C1	Solute carrier organic anion transporter family member 4C1	0.990	landscape →
Q8BGD4	—	0.988	Q8BGD4 →
Q8R3L5	—	0.988	Q8R3L5 →
Q71MB6	—	0.988	Q71MB6 →
Q99N02	—	0.987	Q99N02 →
Q8HYW2	—	0.987	Q8HYW2 →